<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077033</url>
  </required_header>
  <id_info>
    <org_study_id>ERIDEK-0086/2020</org_study_id>
    <nct_id>NCT05077033</nct_id>
  </id_info>
  <brief_title>Intratumoral phIL12 GET</brief_title>
  <acronym>SmartGeneH&amp;N</acronym>
  <official_title>Treatment of Skin Tumours With Intratumoral Interleukin 12 Gene Electrotransfer in the Head and Neck Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electroporation provides non-viral gene delivery method for plasmid DNA. Its clinical&#xD;
      application was already proven in preclinical and in clinical trial in treatment of melanoma&#xD;
      skin metastases with plasmid coding IL-12, in USA. Intratumoral gene transfer of plasmid&#xD;
      coding for IL-12 has proven safe end effective, having good local tumour control and some&#xD;
      evidence indicates on abscopal effect. The EU directives recommend the use of plasmids&#xD;
      without the gene for antibiotic resistance. For this purpose we constructed plasmid coding&#xD;
      for IL-12 in accordance with the EU regulatory requirements.&#xD;
&#xD;
      In the proposed study we intend to study the safety and tolerability of the constructed&#xD;
      plasmid, phIL12, in treatment of basal cell carcinomas in patients with operable tumors in&#xD;
      head and neck region. The study is designed as exploratory, dose escalating with the aim to&#xD;
      determine the dose of plasmid that produces IL-12 expression in the tumours with best&#xD;
      biological activity, infiltration of the immune cells and no toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of acute adverse events</measure>
    <time_frame>Adverse events 2 days after the treatment.</time_frame>
    <description>CTCAE v.5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events 7 days after the treatment</measure>
    <time_frame>Adverse events 7 days after the treatment.</time_frame>
    <description>CTCAE v.5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of late adverse events</measure>
    <time_frame>Adverse events 30 days after the treatment.</time_frame>
    <description>CTCAE v.5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating quality of life with questionnaire one week after the treatment</measure>
    <time_frame>Changes from baseline 7 days after the treatment.</time_frame>
    <description>EORTC QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluating quality of life with questionnaire one month after the treatment</measure>
    <time_frame>Changes from baseline 30 days after the treatment.</time_frame>
    <description>EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Changes from baseline at 2, 7 and 30 days after the treatment.</time_frame>
    <description>Determination of serum levels of IL-12 cytokine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of IL-12 and IFN-y in tumor samples</measure>
    <time_frame>Changes from baseline at 7 and 30 days after the treatment.</time_frame>
    <description>Determination of tumor IL-12 and IFN-y levels in tumor biopsies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intratumoral phIL12 gene electrotransfer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phIL12 GET</intervention_name>
    <description>intratumoral phIL12 gene electrotransfer</description>
    <arm_group_label>Intratumoral phIL12 gene electrotransfer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed, previously untreated cutaneous basal cell&#xD;
             carcinoma located in head and neck region.&#xD;
&#xD;
          -  Solitary tumors, with largest diameter up to 3 cm, in the region where curative&#xD;
             surgery is feasible.&#xD;
&#xD;
          -  Age 18-years or older.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Physical performance in accordance with the Karnofsky scale ≥ 70 or &lt; 2 in accordance&#xD;
             with World Health Organization (WHO) scale.&#xD;
&#xD;
          -  The patient must be capable of understanding the treatment procedure and possible&#xD;
             adverse events, which may arise during treatment.&#xD;
&#xD;
          -  The patient must be capable of signing the informed consent to participate in the&#xD;
             clinical study (voluntary and conscientious consent after education).&#xD;
&#xD;
          -  Prior to inclusion in the trial, the patient must be presented at a multidisciplinary&#xD;
             advisory team meeting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known malignancy elsewhere in/on the body.&#xD;
&#xD;
          -  Lesions not suitable for treatment with GET (invasion into the bone, infiltration of&#xD;
             large vessels).&#xD;
&#xD;
          -  A life-threatening infection and/or severe heart failure and/or liver failure and/or&#xD;
             other life-threatening systemic diseases.&#xD;
&#xD;
          -  Significantly reduced lung function, which requires the determination of DLCO.&#xD;
             Patients should not be treated if DLCO is abnormal.&#xD;
&#xD;
          -  Treatment with immunosuppressive drugs, steroids and other drugs that would affect&#xD;
             poor wound healing.&#xD;
&#xD;
          -  Age under 18-years.&#xD;
&#xD;
          -  Major disruptions in the coagulation system (who does not respond to the standard&#xD;
             therapy - replacement of vitamin K or freshly frozen plasma).&#xD;
&#xD;
          -  A chronic decline in the kidney function (creatinine &gt; 150 µmol/L).&#xD;
&#xD;
          -  Epilepsy.&#xD;
&#xD;
          -  Pregnancy and breast-feeding.&#xD;
&#xD;
          -  The patient's incapability of comprehending the purpose or course of the trial, or not&#xD;
             agreeing to be included in the trial.&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol requirements and scheduled&#xD;
             visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gregor Sersa, PhD</last_name>
    <phone>+386 (0)1 5879 434</phone>
    <email>gsersa@onko-i.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Primoz Strojan, PhD</last_name>
    <phone>+386 (0)1 5879 290</phone>
    <email>pstrojan@onko-i.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Primoz Strojan, PhD, MD</last_name>
      <phone>+386 (0)1 5879 290</phone>
      <email>pstrojan@onko-i.si</email>
    </contact>
    <investigator>
      <last_name>Primoz Strojaan, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregor Sersa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maja Cemazar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Jesenko, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masa Bosnjak, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bostjan Markelc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ursa Lampreht Tratar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kloboves Veronika, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gasljevic Gorana, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreja Brozic, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana, Department of Otorhinolaryngology and Cervicofacial Surgery</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ales Groselj, MD, PhD</last_name>
      <phone>+386 (0)1 5222 153</phone>
      <email>ales.groselj@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Ales Groselj, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Crt Jamsek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandar Anicin, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

